Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Opinion: Governments Must Take 'Concrete Action' To Reduce Maternal Mortality, Morbidity
With the U.N. Human Rights Council"s June session coming up, governments have a "chance to prove that they value women"s lives by taking concrete action" to recognize "preventable maternal death as a violation of women"s rights," Mary Robinson and Alicia Yamin, advisory council members of the International Initiative on Maternal Mortality and Human Rights, write in a Boston Globe opinion piece.

Battles Over Insurance Reform Afflict House Dems
"House liberals are offended that Speaker Nancy Pelosi (D-Calif.) mocked their threats to oppose a Democratic healthcare bill, saying leaders are underestimating their frustration over a deal cut with centrist Blue Dogs," The Hill reports. "Rep. Lynn Woolsey (D-Calif.), co-chairwoman of the Congressional Progressive Caucus, on Monday expressed outrage at the comments and said her group is being "laughed at." Woolsey is the author of a letter signed by 60 fellow House liberals vowing to vote against a deal cut with the Blue Dogs ... Woolsey said the signers of the letter plan to "remind leadership" of the group"s support for a "robust public option." "Robust" to liberals generally means similar to Medicare. Liberals are irritated leaders granted Blue Dogs" concessions that prevent the public option from using Medicare rates for reimbursement. They believe that will make care too expensive for many people" (Soraghan and Allen, 8/3).
News of the day
Breast Cancer Etiology May Vary By Subtype
Women"s reproductive and lifestyle characteristics can be linked to different invasive breast cancer subtypes. Data on 2544 breast cancer cases, presented in the open access journal Breast Cancer Research, suggests that traditional risk factors for development of the condition are associated with different kinds of tumor.
Cardiovascular

Sirona Biochem Starts Testing First Batch Of Drug Candidates Designed To Combat Diabetes And Obesity

Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that it has now taken delivery of its first batch of unique SGLT compounds from its French partner TFChem (Rouen, France) for screening and evaluation. "The successful production of these new molecules marks a significant company milestone," said CEO, Dr. Howard Verrico. Sirona Biochem owns the worldwide product rights to a library of sodium glucose transporter (SGLT) inhibitors to treat diabetes and obesity. SGLT Inhibitors block the reuptake of excess sugars from urine in the kidney which can then reduce high blood sugar to normal levels. It"s estimated that there are nearly 21 million people in the United States, or 7% of the population, who are diabetic. About 15 million have been diagnosed with the disease, but over 6 million people are unaware that they are suffering from it. It is forecast that by 2025, 333 million people will have diabetes. Management of sugar metabolism is a primary medical challenge associated with treating diabetes and obesity. Dr. Verrico explained that, "As far as we have been able to verify, these are a truly unique group of SGLT inhibitors in the world. To our knowledge, TFChem is the first to synthesize these uniquely designed molecules. SGLT inhibitors are a new and exciting class of compounds that have great promise for the treatment of diabetes and obesity. "This new drug class is one considered to have substantial market potential in the fight against diabetes and obesity, particularly if we can prove our versions to be robust enough to survive the journey through the body and result in reduced blood sugar levels. "The test results will then enable us, through ongoing refinement of molecular development, to identify our lead compounds for in vivo testing projected to start early next year," concluded Dr. Verrico. The tests were developed by SignalChem (Richmond, BC). Sirona"s scientific team aims to identify lead compounds by the end of 2009. Sirona Biochem"s website is at -- http://www.sironabiochem.com -- where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466. About Sirona Biochem Sirona Biochem Corp. (TSX-V: SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as SGLT Inhibitors. SGLT inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity. http://www.sironabiochem.com. About TFChemistry TFChem, of Rouen, France, is a drug-discovery company which uses fluorine atom properties to develop new glycomimetic compounds: the GlycoMim® technology. TFChem is a leader in the area of fluorinated glycosides and their application as new, more potent and safer drugs. Through application of the patented core technology it is the intention to modify and discover new carbohydrate based drug compounds with increased therapeutic properties and clinical improvement potential. Sirona Biochem


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009